Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

News and Events

Trovagene (TROV) Stock: Providing New Cancer Treatment Options With Onvansertib CNA Article

Please see write-up on Trovagene by CNA.  

Click Here to Read Article